Buchumschlag

Relapsed/refractory acute myeloid leukemia: any progress?

Aim of this review was to focus on prognostic and predictive factors, standard and new treatment approaches, and on statistical considerations for future clinical trials in patients with relapsed/refractory acute myeloid leukemia (r/r-AML). New prognostic molecular markers were identified in r/r-AML...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Schlenk, Richard Friedrich (VerfasserIn) , Müller-Tidow, Carsten (VerfasserIn) , Benner, Axel (VerfasserIn) , Kieser, Meinhard (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2017
In: Current opinion in oncology
Year: 2017, Jahrgang: 29, Heft: 6, Pages: 467-473
ISSN:1531-703X
DOI:10.1097/CCO.0000000000000404
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1097/CCO.0000000000000404
Verlag, Volltext: https://insights.ovid.com/pubmed?pmid=28857842
Volltext
Verfasserangaben:Richard F. Schlenk, Carsten Müller-Tidow, Axel Benner, and Meinhard Kieser

MARC

LEADER 00000caa a2200000 c 4500
001 1574984020
003 DE-627
005 20230427042858.0
007 cr uuu---uuuuu
008 180511s2017 xx |||||o 00| ||eng c
024 7 |a 10.1097/CCO.0000000000000404  |2 doi 
035 |a (DE-627)1574984020 
035 |a (DE-576)504984020 
035 |a (DE-599)BSZ504984020 
035 |a (OCoLC)1341009521 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Schlenk, Richard Friedrich  |d 1965-  |e VerfasserIn  |0 (DE-588)129025380  |0 (DE-627)387778004  |0 (DE-576)297454102  |4 aut 
245 1 0 |a Relapsed/refractory acute myeloid leukemia  |b any progress?  |c Richard F. Schlenk, Carsten Müller-Tidow, Axel Benner, and Meinhard Kieser 
264 1 |c 2017 
300 |a 7 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 11.05.2018 
520 |a Aim of this review was to focus on prognostic and predictive factors, standard and new treatment approaches, and on statistical considerations for future clinical trials in patients with relapsed/refractory acute myeloid leukemia (r/r-AML). New prognostic molecular markers were identified in r/r-AML, FLT3-ITD, mutated IDH1, and biallelic CEBPA mutations. Intensive combination chemotherapy including gemtuzumab ozogamicin emerged as an effective salvage therapy in refractory AML. Timing of allo-HCT in r/r-AML may be oriented at the probability to achieve a response to intensive salvage therapy. Several new treatment approaches ranging from new and modified cytotoxic drugs to targeted approaches are in clinical development with first efficacy assessment in single-arm phase II studies. Their external validity may be considerably increased by using a novel design based on a matching approach. FLT3-ITD, mutated IDH1, and biallelic CEBPA mutations are identified as prognostic molecular markers in r/r-AML. Timing of allo-HCT should be based on the probability to achieve a response to intensive salvage therapy. Several new approaches are currently evaluated and matching for controls may help to increase external validity. 
700 1 |a Müller-Tidow, Carsten  |d 1968-  |e VerfasserIn  |0 (DE-588)1015101798  |0 (DE-627)705330230  |0 (DE-576)351197893  |4 aut 
700 1 |a Benner, Axel  |d 1959-  |e VerfasserIn  |0 (DE-588)106584686X  |0 (DE-627)81687221X  |0 (DE-576)425536602  |4 aut 
700 1 |a Kieser, Meinhard  |d 1960-  |e VerfasserIn  |0 (DE-588)103276547X  |0 (DE-627)739277766  |0 (DE-576)168963825  |4 aut 
773 0 8 |i Enthalten in  |t Current opinion in oncology  |d Philadelphia, Pa. : Lippincott Williams & Wilkins, 1989  |g 29(2017), 6, Seite 467-473  |h Online-Ressource  |w (DE-627)324455887  |w (DE-600)2026986-9  |w (DE-576)093981147  |x 1531-703X  |7 nnas  |a Relapsed/refractory acute myeloid leukemia any progress? 
773 1 8 |g volume:29  |g year:2017  |g number:6  |g pages:467-473  |g extent:7  |a Relapsed/refractory acute myeloid leukemia any progress? 
856 4 0 |u http://dx.doi.org/10.1097/CCO.0000000000000404  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://insights.ovid.com/pubmed?pmid=28857842  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20180511 
993 |a Article 
994 |a 2017 
998 |g 103276547X  |a Kieser, Meinhard  |m 103276547X:Kieser, Meinhard  |d 910000  |d 999701  |e 910000PK103276547X  |e 999701PK103276547X  |k 0/910000/  |k 1/910000/999701/  |p 4  |y j 
998 |g 106584686X  |a Benner, Axel  |m 106584686X:Benner, Axel  |d 50000  |e 50000PB106584686X  |k 0/50000/  |p 3 
998 |g 1015101798  |a Müller-Tidow, Carsten  |m 1015101798:Müller-Tidow, Carsten  |d 910000  |d 910100  |e 910000PM1015101798  |e 910100PM1015101798  |k 0/910000/  |k 1/910000/910100/  |p 2 
998 |g 129025380  |a Schlenk, Richard Friedrich  |m 129025380:Schlenk, Richard Friedrich  |d 50000  |e 50000PS129025380  |k 0/50000/  |p 1  |x j 
999 |a KXP-PPN1574984020  |e 3009146833 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"roleDisplay":"VerfasserIn","role":"aut","display":"Schlenk, Richard Friedrich","given":"Richard Friedrich","family":"Schlenk"},{"given":"Carsten","role":"aut","roleDisplay":"VerfasserIn","display":"Müller-Tidow, Carsten","family":"Müller-Tidow"},{"family":"Benner","given":"Axel","role":"aut","roleDisplay":"VerfasserIn","display":"Benner, Axel"},{"family":"Kieser","given":"Meinhard","display":"Kieser, Meinhard","role":"aut","roleDisplay":"VerfasserIn"}],"id":{"eki":["1574984020"],"doi":["10.1097/CCO.0000000000000404"]},"note":["Gesehen am 11.05.2018"],"name":{"displayForm":["Richard F. Schlenk, Carsten Müller-Tidow, Axel Benner, and Meinhard Kieser"]},"physDesc":[{"extent":"7 S."}],"origin":[{"dateIssuedDisp":"2017","dateIssuedKey":"2017"}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"1989-","publisherPlace":"Philadelphia, Pa. ; [Erscheinungsort nicht ermittelbar]","publisher":"Lippincott Williams & Wilkins ; Ovid","dateIssuedKey":"1989"}],"disp":"Relapsed/refractory acute myeloid leukemia any progress?Current opinion in oncology","recId":"324455887","title":[{"title_sort":"Current opinion in oncology","title":"Current opinion in oncology"}],"pubHistory":["1.1989 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"id":{"eki":["324455887"],"zdb":["2026986-9"],"issn":["1531-703X"]},"part":{"extent":"7","issue":"6","volume":"29","year":"2017","pages":"467-473","text":"29(2017), 6, Seite 467-473"},"note":["Gesehen am 27.01.2025"]}],"recId":"1574984020","title":[{"title_sort":"Relapsed/refractory acute myeloid leukemia","subtitle":"any progress?","title":"Relapsed/refractory acute myeloid leukemia"}]} 
SRT |a SCHLENKRICRELAPSEDRE2017 

Ähnliche Einträge